This group of patients presenting a NASH score of ≥ 4 showed higher blood pressures and, as expected, higher Fibroscan values, higher levels of AST and ALT, and higher scores on the non-invasive hepatic steatosis index (HIS), non-alcoholic fatty liver disease fibrosis score (NFS) index and AST to platelet ratio index (APRI). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.